secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2023-01-24T23:59:59+00:00
Accession:  0001193125-23-014226
Event type: regulatory
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase receives Nasdaq extension to July 24, 2023 to regain $1 minimum bid price compliance
--------------------------------------------------------------------------------

- Nasdaq granted additional 180-day period until July 24, 2023 to meet Minimum Bid Price Requirement.
- Compliance requires closing bid price at least $1.00 for 10 consecutive business days.
- Company previously disclosed deficiency on July 25, 2022; intends to cure via reverse stock split if needed.
- Failure to demonstrate compliance by July 24, 2023 will result in Nasdaq delisting notice, with appeal rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312523014226/0001193125-23-014226-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312523014226/d355336d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-014226

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer